Cytokinetics Inc
(NAS:CYTK)
$
48.3
-0.68 (-1.39%)
Market Cap: 5.06 Bil
Enterprise Value: 5.20 Bil
PE Ratio: 0
PB Ratio: 0
GF Score: 43/100 Cytokinetics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 09, 2021 / 07:00PM GMT
Release Date Price:
$21.53
(-0.87%)
Graig Suvannavejh
Goldman Sachs Group, Inc., Research Division - Executive Director & Senior Equity Research Analyst
All right. Well, good afternoon, everyone, and welcome to the 3:00 p.m. Eastern Time session here on Day 2 of the 42nd Annual Goldman Sachs Global Healthcare Conference. My name is Graig Suvannavejh, and I cover U.S. and European Biopharma companies here at the firm. It's my great pleasure to be hosting Cytokinetics today in a fireside chat. And with that, let me welcome the company's CEO, Robert Blum; and the company's Head of R&D, Fady Malik. Gentlemen, great to see you both, and welcome to the conference.
Robert I. Blum
Cytokinetics, Incorporated - CEO, President & Director
Thank you, Graig. Thank you for having us here.
Graig Suvannavejh
Goldman Sachs Group, Inc., Research Division - Executive Director & Senior Equity Research Analyst
I believe that, Robert, you wanted to start off with perhaps some introductory comments, and I think you have a slide deck that you want to share.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot